Abstract:Breast cancer is the 2nd leading cause of cancer related deaths among women in the US with over 240,000 diagnoses and 40,000 deaths expected in 2014. Among the more serious and deadly forms of breast cancer are the Triple Negative Breast Cancers (TNBC) (ER-, PR-, HER2-). Mortality rates among patients rise dramatically when these cancers spread beyond the primary tumor site. Therefore reduction of tumor cell dispersion is a key component to minimizing mortality rates. Epithelial-Mesenchymal Transition (EMT) is the process by which cancer cells downregulate proteins associated with cell to cell adhesion (e.g. E-cadherin) resulting in cells that are able to detach from neighboring cancer cells, invade adjacent tissue, and eventually enter the circulatory system or lymphatics. The process of EMT is tightly regulated by the transcription factor Twist1, which is often overexpressed in breast cancer. Therefore, Twist1 serves as an excellent therapeutic target whose downregulation would result in fewer metastatic cancer cells and correspondingly reduce cancer mortality. Our lab has designed and tested (in vitro) two siRNA based therapeutics that target Twist1 in a TNBC cell line (SUM 1315). These siRNA molecules have been strategically designed and modified to make them resistant to degradation, enhance silencing effects and diminish their immunogenicity. To overcome the inherent problems with delivery of siRNA (both in vitro and in vivo) we have been testing two nanoparticle delivery systems. Recent advances in nanotechnology have led to the development of a variety of nanoparticles that provide valuable tools for cancer therapy. We are testing two different types of nanoparticles in this study: The first is a Polyamidoamine (PAMAM) dendrimer (YTZ3-15) which is a truncated 3rd generation dendrimer which has been modified with a lipophilic tail to enhance cellular uptake. The second is a mesoporous silica nanoparticle (MSNs) which is able to not only deliver siRNA, but is also contains pores which allow simultaneously delivering chemotherapies such as doxorubicin. This novel siRNA gene silencing and nanotechnology-based therapy should allow us to exert more precise temporal control during breast cancer treatment. When complexed with either nanoparticle we have found significant Twist1 knock down in vitro as well as reduction of Twist1 target genes that are associated with EMT. We have also shown that Twist1 silencing reduces migration and invasion of SUM 1315 breast cancer cells in vitro Recently we began testing these siRNA+Nanoparticle complexes in an orthotopic murine model using Firefly Luciferase expressing SUM 1315 cells in immunocompromised mice (NSG). The results of this in vivo research have shown that there is significant uptake of the siRNA+Nanoparticle complexes in the tumors when compared to other organs. Results of these studies are significant because TNBC is particularly drug resistant and metastatic; and superior therapies are urgently needed to effectively treat patients with these breast cancers. This approach paves the way for TNBC treatment that incorporates Twist1 knock down (resulting in renewed chemosensitivity) and simultaneous delivery of a chemotherapy reagent. Citation Format: James B Finlay, Cai M Roberts, Gina Lowe, Ling Peng, Jeff I Zink, Fuyuhiko Tamanoi, Carlotta A Glackin. Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-07-04.

Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133 + cells in triple-negative breast cancer

Anti-angiogenic Treatment Promotes Triple-Negative Breast Cancer Invasion Via Vasculogenic Mimicry

Hypoxia Induced Epithelial–mesenchymal Transition and Vasculogenic Mimicry Formation by Promoting Bcl-2/Twist1 Cooperation

Sunitinib Facilitates Metastatic Breast Cancer Spreading by Inducing Endothelial Cell Senescence

Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells

Hypoxia Promotes Vasculogenic Mimicry Formation By The Twist1-Bmi1 Connection In Hepatocellular Carcinoma

Twist May Be Associated with Invasion and Metastasis of Hypoxic NSCLC Cells

Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.

Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry.

Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth but Promotes Metastasis.

Role of Twist in Vasculogenic Mimicry Formation in Hypoxic Hepatocellular Carcinoma Cells in Vitro.

HIF-2α Promotes the Formation of Vasculogenic Mimicry in Pancreatic Cancer by Regulating the Binding of Twist1 to the VE-cadherin Promoter.

Promotion of Tumor Cell Metastasis and Vasculogenic Mimicry by Way of Transcription Coactivation by Bcl-2 and Twist1: a Study of Hepatocellular Carcinoma.

Modulating the Tumor Immune Microenvironment with Sunitinib Malate Supports the Rationale for Combined Treatment with Immunotherapy.

Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancer

Stem-like Tumor Cells Involved in Heterogeneous Vasculogenesis in Breast Cancer

DCE-MRI of Sunitinib-Induced Changes in Tumor Microvasculature and Hypoxia: A Study of Pancreatic Ductal Adenocarcinoma Xenografts

Cd133(+) Cells with Cancer Stem Cell Characteristics Associates with Vasculogenic Mimicry in Triple-Negative Breast Cancer

Vasculogenic Mimicry and Expression of Twist1 and Kai1 Correlate with Metastasis and Prognosis in Lung Squamous Cell Carcinoma

Treatment Of Metastatic Breast Cancer Using Two Nanoparticles Combined With Sirna Targeting Twist1 To Inhibit Emt

Vandetanib alters the tumoricidal capacity of human breast cancer stem cells via inhibiting vasculogenic capacity